MX2009004290A - Cathepsin proteases inhibitors. - Google Patents

Cathepsin proteases inhibitors.

Info

Publication number
MX2009004290A
MX2009004290A MX2009004290A MX2009004290A MX2009004290A MX 2009004290 A MX2009004290 A MX 2009004290A MX 2009004290 A MX2009004290 A MX 2009004290A MX 2009004290 A MX2009004290 A MX 2009004290A MX 2009004290 A MX2009004290 A MX 2009004290A
Authority
MX
Mexico
Prior art keywords
optionally substituted
alkynyl
alkenyl
proteases inhibitors
cathepsin proteases
Prior art date
Application number
MX2009004290A
Other languages
Spanish (es)
Inventor
Robert Epple
Ross Russo
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of MX2009004290A publication Critical patent/MX2009004290A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Abstract

The invention provides compounds (I) and pharmaceutical compositions thereof, and more particularly, bicyclic carbamates, which are useful as cathepsin inhibitors, and methods for using such compounds or pharmaceutically acceptable salts thereof, wherein X is 0 or S; R1 is OR2, halo, (CR2)nR3, nitro, cyano, amino, aniido, sulfonamide, or an optionally substituted C1-6 alkyl, C2-6 alkenyl, or C3-6 alkynyl;R2 is H, (CR2)nR3, or an optionally substituted C1-6alkyl, C2-6 alkenyl or C3-6 alkynyl; R3 is an optionally substituted aryl, heteroaryl, carbocyciic ring or heterocyclic ring; m is 1-3; and n is 0-4.
MX2009004290A 2006-10-23 2007-10-17 Cathepsin proteases inhibitors. MX2009004290A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86250006P 2006-10-23 2006-10-23
PCT/US2007/081635 WO2008051763A1 (en) 2006-10-23 2007-10-17 Cathepsin proteases inhibitors

Publications (1)

Publication Number Publication Date
MX2009004290A true MX2009004290A (en) 2009-07-27

Family

ID=39091868

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004290A MX2009004290A (en) 2006-10-23 2007-10-17 Cathepsin proteases inhibitors.

Country Status (9)

Country Link
EP (1) EP2078027A1 (en)
JP (1) JP2010507681A (en)
KR (1) KR20090064463A (en)
CN (1) CN101589047A (en)
AU (1) AU2007309195A1 (en)
BR (1) BRPI0717348A2 (en)
CA (1) CA2667816A1 (en)
MX (1) MX2009004290A (en)
WO (1) WO2008051763A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101881596B1 (en) 2008-12-02 2018-07-24 웨이브 라이프 사이언시스 재팬 인코포레이티드 Method for the synthesis of phosphorous atom modified nucleic acids
SG177564A1 (en) 2009-07-06 2012-02-28 Ontorii Inc Novel nucleic acid prodrugs and methods of use thereof
WO2012039448A1 (en) 2010-09-24 2012-03-29 株式会社キラルジェン Asymmetric auxiliary group
EP2734208B1 (en) 2011-07-19 2017-03-01 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
KR102213609B1 (en) 2012-07-13 2021-02-08 웨이브 라이프 사이언시스 리미티드 Chiral control
EP2872485B1 (en) 2012-07-13 2020-12-16 Wave Life Sciences Ltd. Asymmetric auxiliary group
JPWO2015108048A1 (en) 2014-01-15 2017-03-23 株式会社新日本科学 Chiral nucleic acid adjuvant and antitumor agent having antitumor activity
WO2015108047A1 (en) 2014-01-15 2015-07-23 株式会社新日本科学 Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
AU2015207773B2 (en) 2014-01-16 2021-06-17 Wave Life Sciences Ltd. Chiral design
US10017463B2 (en) 2014-07-21 2018-07-10 Brandeis University Inhibitors of deubiquitinating proteases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (en) * 2000-08-01 2002-10-11 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS, PREPARATION AND USE AS MEDICAMENTS IN PARTICULAR AS ANTI-BACTERIALS
FR2835186B1 (en) * 2002-01-28 2006-10-20 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS ACTIVE AS BETA-LACTAMASES INHIBITORS
US7297714B2 (en) * 2003-10-21 2007-11-20 Irm Llc Inhibitors of cathepsin S

Also Published As

Publication number Publication date
EP2078027A1 (en) 2009-07-15
CN101589047A (en) 2009-11-25
CA2667816A1 (en) 2008-05-02
BRPI0717348A2 (en) 2013-10-15
KR20090064463A (en) 2009-06-18
WO2008051763A1 (en) 2008-05-02
AU2007309195A1 (en) 2008-05-02
JP2010507681A (en) 2010-03-11

Similar Documents

Publication Publication Date Title
MX2009004290A (en) Cathepsin proteases inhibitors.
NO2023022I1 (en) cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate
NO20090628L (en) Pyridizinone derivatives
EA200500203A1 (en) NEW METHOD OF SYNTHESIS AND NEW CRYSTAL FORM OF AGOMELATIN AND PHARMACEUTICAL COMPOSITIONS THAT HERE CONTAINS
EA200900959A1 (en) MEK INHIBITORS
WO2007026920A3 (en) Amide derivatives as rock inhibitors
NO20073791L (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
JO2962B1 (en) Substituted aminopropionic derivatives as neprilysin inhibitors
NO20071050L (en) Rapamycin polymorph II and uses thereof
NO20080186L (en) Heterocyclic aspartyl protease inhibitors, preparation and use thereof
BRPI0507903A (en) quinazoline derivatives and pharmaceutical composition comprising the same
NO20076554L (en) Pyrimidine or triazine condensed bicyclic metalloprotease inhibitors
DE602005024274D1 (en) AS AURORA KINASE INHIBITORS USEFUL THIENOPYRIMIDINE
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
ECSP099335A (en) HETEROCYCLIC COMPOUNDS CONTAINING NITROGEN AND METHODS OF USE OF THE SAME
EA200900613A1 (en) SPIROKETONE ACETYL-COA-CARBOXYLAS INHIBITORS
WO2007125310A3 (en) Pharmaceutical combinations of pk inhibitors and other active agents
BRPI0713446A2 (en) prolyl hydroxylase inhibitors
NO20092692L (en) MAPK / ERK kinase inhibitors
EA200900135A1 (en) DERIVATIVES OF PYRAZOL AS A CYTOCHROME P450 INHIBITORS
EA200800542A1 (en) PYRIDINAMINOSULPHONE-SUBSTITUTED BENZAMIDES AS CYTOCHROME P450 3A4 INHIBITORS (CYP3A4) INHIBITORS
EA200801199A1 (en) KINASE INHIBITORS
ATE553106T1 (en) HETEROARYLPYRROLOPYRIDINONES AS KINASE INHIBITORS
NO20085107L (en) Spirocyclic nitriles as protease inhibitors
WO2009010789A3 (en) Pyrimidine derivatives 934

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal